Aurobindo Pharma (AUROPHARMA) | Stock Overview & Key Data
Aurobindo Pharma Performance Comparison
Stock Range
Today's Range
Low: ₹1,086.80
High: ₹1,102.60
on October 3, 2025
52 Week Range
Low: ₹1,010.00
High: ₹1,520.05
on April 7, 2025
on October 9, 2024
All-Time High: ₹1,592.00 on September 9, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR635.3B
EPS
58.29
P/E Ratio (TTM)
18.65
Forward P/E
17.45
P/B Ratio
1.93
PEG Ratio
-1.96
Div. Yield
0.38%
ROE
10.68%
Beta
0.137
Debt to Equity
25.31
Financial Highlights
Profitability
Gross Margin
58.43%
Operating Margin
15.22%
Profit Margin
10.59%
Returns and Earnings
Return on Assets (TTM)
7.00%
Return on Equity (TTM)
10.68%
EBITDA
INR70.6B
Net Income (TTM)
INR33.9B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR551.39
Quarterly Revenue Growth (YoY)
4.00%
Quarterly Earnings Growth (YoY)
-10.30%
Dividend Information
Last 12-Month Dividend
₹4.00
Current Dividend Yield
0.38%
3-Year Average Dividend Yield
0.36%
3-Year Average Annual Dividend
₹3.83
3-Year Total Dividends
₹11.50
Ex-Dividend Date
August 8, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma AUROPHARMA | 635.28B Large-cap | 0.30% | 5.64% | -5.43% | -7.06% | -19.21% | -25.43% | 102.50% | 31.00% |
| Sun Pharmaceutical SUNPHARMA | 4.01T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Torrent TORNTPHARM | 1.24T Large-cap | -1.30% | -2.55% | 5.42% | 8.22% | 2.81% | 1.18% | 123.52% | 25.54% |
| Cipla CIPLA | 1.22T Large-cap | 1.22% | -3.85% | 0.60% | 1.47% | 2.59% | 5.43% | 34.25% | 88.97% |
| Dr. Reddy's DRREDDY | 1.05T Large-cap | -0.40% | -1.12% | -3.35% | 8.39% | -8.83% | -5.92% | 42.59% | 21.10% |
Ownership & Short Interest
Insider Ownership
54.10%
Institutional Ownership
30.17%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AUROPHARMA's 52-week high and low?
- In the last 52 weeks, Aurobindo Pharma reached a high of ₹1,520.05 (on October 9, 2024) and a low of ₹1,010.00 (on April 7, 2025).
- What is the market cap and P/E ratio for AUROPHARMA?
- Curious about Aurobindo Pharma's size and valuation? Its market capitalization stands at 635.28B. When it comes to valuation, the P/E ratio (trailing twelve months) is 18.65, and the forward P/E (looking ahead) is 17.45.
- Does AUROPHARMA pay dividends? If so, what's the yield?
- Yes, Aurobindo Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.38%, and the company has paid an average of ₹3.83 per share annually over the past 3 years.
- Who are Aurobindo Pharma's main competitors or similar companies to consider before investing?
When looking at Aurobindo Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA4.01T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Torrent
TORNTPHARM1.24T Healthcare Drug Manufacturers - Specialty & Generic 1.18% 123.52% Cipla
CIPLA1.22T Healthcare Drug Manufacturers - Specialty & Generic 5.43% 34.25% Dr. Reddy's
DRREDDY1.05T Healthcare Drug Manufacturers - Specialty & Generic -5.92% 42.59% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aurobindo Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aurobindo Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.68%, the Debt to Equity ratio from the most recent quarter is 25.31, and its Gross Profit Margin stands at 58.43%.
- What is the recent revenue and earnings growth for AUROPHARMA?
- Looking at Aurobindo Pharma's growth, its revenue over the trailing twelve months (TTM) was INR320B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.00%, and quarterly earnings saw a YoY growth of -10.30%.
- How much of AUROPHARMA stock is held by insiders and institutions?
- Wondering who owns Aurobindo Pharma stock? Company insiders (like executives and directors) hold about 54.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.17%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.